Novolog (NVLG) Q3 2025 earnings summary

Executive summary

• Nine-month 2025 revenue was ₪2,021.6 million, with net profit of ₪40.99 million and Adjusted EBITDA of ₪95.7 million.

• Q3 2025 revenue was ₪483.6 million, net income was ₪4.3 million, and Adjusted EBITDA was ₪32.2 million.

• The company operates in logistics, healthcare, and digital health, remaining profitable across all segments.

• A dividend of ₪10 million (₪0.019574 per share) was declared, payable December 8, 2025.

• Full acquisition of Pronto Diagnostics completed in September 2025.

Financial highlights

• Q3 2025 revenue decreased 12.2% year-over-year; gross profit fell 16.4% to ₪37.1 million.

• Nine-month 2025 revenue declined 3.4% year-over-year; gross profit was ₪180.8 million.

• Adjusted EBITDA for nine months was ₪95.7 million, up from ₪85.99 million year-over-year.

• Cash flow from operating activities for the nine months was ₪158.5 million.

• Total assets as of September 30, 2025, were ₪3,037.1 million.

Outlook and guidance

• Adjusted EBITDA for 2025 is projected at ₪96–102 million, excluding extraordinary events.

• The company is implementing an efficiency plan in logistics to address SAP-related disruptions and expand health services.

• No material negative impact is expected from the end of the Gaza conflict or Israel's credit rating changes.